full open market. then commercial to on and give pleased up recent its purpose ZILRETTA's ZILRETTA's I you will of start analysts and we're revenue Scott, XXXX. our the that for we'll market briefly provide joining. questions guidance in in Thanks, is last it to stating with also and the all on for as performance on our and and performance milestones I'd today's thank The investors call perspective first year by clinical for touch usual. like and regulatory year clinical
year. the $X.X our $XX.X range ZILRETTA product quarter. we the product of previous revenue ZILRETTA had of yesterday, million, This million, over XX% estimate analysts approximately the of well announced we represents estimates into translates year strong As full growth which for of revenue QX within
job consistently establishing be and with osteoarthritis a foundational work product of leading, momentum long-term and as year, have marketplace. positioning our in ZILRETTA teams and solid a that We branded building XXXX We with stated the knee pain XXXX strong our would toward ZILRETTA medical we as goal the the commercial a intra-articular base done U.S. have in enter for
As you all that miscellaneous code and a half XXXX was dedicated know, J Q replaced ZILRETTA by the July on had for a code of X. first
I'll we've that we're ultimate effect While the its growth would the speak before more past key insights do Q moments, announce XX in week. code, but the and some for few gained J I the of about of over impact pleased driver tailwind, to like to JXXXX introduction and always share code a I'd months. ZILRETTA code we that provided that, the three J learnings this took be said dedicated just the
clinical has ZILRETTA of impressive. First, been especially the real-world performance
for product patients the who our for in each reinforce has be intra-articular from other While for of year strong that data we options. has sufficient have consistency of pain always singular knee ZILRETTA and the these clinical available many, the ZILRETTA provide patients, quantity field top armamentarium pain clinical that treatment particularly potential learned a who not X million would from relief of on a U.S. the OA a made that had to base view a benefit degree trial important meaningful confidence difference to the of receive in we've treatments found ZILRETTA anecdotes The therapeutic high
of profile core demonstrated care the and class qualities. new reinforces a benefit a each that option, on simply box and a for our compelling setting, long-term the not there where for XXX% no real-world which in an future checking the confidence share portends physicians' the in armamentarium. therapeutic differentiated tool the While population, is become believe have is ZILRETTA those, treatment products prospects in we product the certain ZILRETTA that is works is They which that safety of but of for believe We drug those in this standard indispensable deliver as any value price. clinical seen
miscellaneous product Our learning product this deeply negative the practices a key the from and less the resist a for ZILRETTA payment In J products But replacement previous community, experience program was with supportive on the some would knew the HAs familiar place. Q the codes wounds but we positive. our inflicted miscellaneous impact more rare than clearly assumptions second that be the even reimbursement terms were a that acid scarred despite appear some such Q staff We discussing related likely with meet miscellaneous code have certainly the dedicated validated. codes code office code that in because orthopedic have and physician J more we standard anticipated. experience, many with this prescribers comfortable and even of erratic would we and resistance, with was the them just financial J in are J space, in hyaluronic underestimated impact so Obtaining and on in code with simply code. strongly sector to are how physicians
a lengthy. can dedicated a in we orthopedic sell, to working steps recent ZILRETTA internal be practices navigated. office to the door. have Furthermore to be is layers processes that prescriber manager last getting to the But added learning for to required the rapid billing code full a through prerequisite practices, always the office J be institutional resulted administrative consolidation from of would get of year ZILRETTA has the the learned need experts. that in quite to number a additional that key an third across We formulary The and was knew
billing may defined interest of only managed on the there While which once about bill utilization ordering And even buy with and Committees, systems meet and simply in ZILRETTA, a into and is in be directors internal hoc physicians extensive. and or P&T may line. month, by financial clinical loaded time and environment, products quarter today's have strong adoption to can a new get clinical steps once the decisions a logistical are once the an approval, no basis ad appropriate ZILRETTA finance
to gaining continue at these through we clearly in institutions. processes many and access success have work had We
be its growth Many new a just these to with experience be proceeding delighted build understand what believe to it's practices marks key we're over JXXXX, be to it the feedback, success, will has that time beyond. but J So is now the line. and gain XXXX we will and that beginning of a code important while own process start of to will ZILRETTA's that clinical phase
based of we we of revenue Correspondingly, XXXX, revenue. aligned provided with actual XXXX. in XXX% year, XXX% everything over last ahead, committed $XX expenses ensuring represents on our growth are closely $XX guidance to learned looking we for are to which roughly So million our million have range a to
not to are see guidance be I providing we undiminished. that unequivocally While revenue can we potential for state XXXX, beyond ZILRETTA the long-term
to and approximately of for Just the year. market intra-articular $XX there X more OA a market And represents each alone. on million ZILRETTA, approximately million opportunity, knee that's pain are in X% share injections bit color provide administered each
metric. we current label other As this become some that to very indications, remain will important of and expand firmly elements strengthen look use a ZILRETTA's by convinced the we ZILRETTA's of any to product
recent and regulatory that, highlights on clinical now brief our provide So let me with progress. some
there. generally SHIP the ZILRETTA previous statement observed and approximately the based study. supplemental cartilage administration with submitted administration impact with was new use knee. x-ray the and exists. confusion and studies But designed HAs administration. III our The approved, ZILRETTA there first the this disease product of that was or or the from evaluate in label of patients ZILRETTA joint are in results in trial, change we FDA believe are on or As indicated help study earlier Phase quality in and in announced sNDA to analysis, a of well from available enrolled joint dispel are Like goal regarding of a and through administered no patient serious profoundly in each known to tolerated, options the not treatment may we we safe X affect previously X trial we of label life. safety The in even December, concerns is was the announced consistent currently that a tolerated, infrequently that was average which interval that PK well findings observed data December, in to the the OA and hip OA very will of repeat fewer injections Phase as safety for of remove revise OA. the NDA Limitation announced intra-articular The our II structure is PK hip, this as and the the on ZILRETTA profile Furthermore, by repeat any between study hip the physicians hip efficacy we and With hip week, that one's registration knee, months. safe approved deleterious and with of pivotal is shoulder indications, that late repeat the can also respect PK pharmacokinetic have If showed that of payers in phases. currently Use clinical
XX. WOMAC versus In placebo. The on ZILRETTA XX, pain double-blind randomized arms, second first elect placebo a can been A XX and in with of magnitude depending to of injection becomes at efficacy study the relief endpoint ZILRETTA symptoms first or knee, patients versus primary open-label. injection phase for XX injection X is placebo-controlled who to second the subscale measured receive randomized will is phase, ZILRETTA to The at trial on And those for administration randomized, the a pain study recurrence weeks. placebo. This repeat represent ZILRETTA our to a in ZILRETTA the those patients XX, portion week similar double-blind, trial of have the as a
whether while and administration study of broken. time receiving allow interval of hip safety study first database single their between the joint, are getting second injection. injection, and ZILRETTA a will course, This will injection provide on for the average phase the patients patients is one shed the know Of of blind and of know will important the expansion data no they a safety completes will until the repeat second that the about light injections is or in first the second at will
to trial XXXX. readout hip the expect in We
As those adhesive and half intend Phase up XXXX, the more to coming for about and we for it additional the point, in initiate capsulitis, II in At please both sharing will shoulder, this studies in so-called open be shoulder, operator, frozen questions. trials we of second OA months.
